Symbols / XRTX Stock $2.97 -1.98% XORTX Therapeutics Inc.

Healthcare • Biotechnology • Canada • NCM
XRTX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Allen Warren Davidoff Ph.D.
Exch · Country NCM · Canada
Market Cap 4.59M
Enterprise Value 3.31M
Income -2.66M
Sales —
FCF (ttm) -1.86M
Book/sh 0.30
Cash/sh 0.62
Employees —
Insider 10d —
IPO Sep 23, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 3.70
PEG —
P/S —
P/B 9.93
P/C —
EV/EBITDA -1.32
EV/Sales —
Quick Ratio 1.58
Current Ratio 2.10
Debt/Eq 1.79
LT Debt/Eq —
EPS (ttm) -2.80
EPS next Y 0.80
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-14
Earnings (prior) 2026-02-26
ROA -46.84%
ROE -98.00%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 1.55M
Shs Float 1.37M
Insider Own 10.26%
Instit Own 5.87%
Short Float 2.93%
Short Ratio 0.49
Short Interest 44.50K
52W High 7.05
vs 52W High -57.87%
52W Low 1.73
vs 52W Low 72.17%
Beta 0.09
Impl. Vol. —
Rel Volume 0.06
Avg Volume 1.28M
Volume 81.48K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $3.03
Price $2.97
Change -1.98%
About

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$2.97
Latest analyst target
3. DCF / Fair value
$-21.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.97
Low
—
High
—
Mean
—
News
RSS: Latest XRTX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-31 Davies Foss (Krysta) Director of Issuer — 0 — —
2025-10-17 Van Damme (Paul Joseph) Director of Issuer — 3,654 $1.00 $3,650
2025-10-17 Van Damme (Paul Joseph) Director of Issuer — 3,132 $0.98 $3,081
2025-07-22 Davidoff, Allen Warren Director of Issuer — 8,191 $0.74 $6,020
2025-06-23 Davidoff, Allen Warren Director of Issuer — 300 $0.87 $262
2025-06-23 Davidoff, Allen Warren Director of Issuer — 500 $0.86 $429
2025-05-14 Davidoff, Allen Warren Director of Issuer — 2,000 $1.02 $2,040
2025-05-14 Davidoff, Allen Warren Director of Issuer — 2,000 $1.02 $2,044
2025-05-12 Davidoff, Allen Warren Director of Issuer — 1,000 $0.73 $733
2025-05-12 Davidoff, Allen Warren Director of Issuer — 300 $1.04 $313
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
3.26
-20.94%
4.12
-31.88%
6.05
-41.25%
10.29
Research And Development
0.57
+212.75%
0.18
-92.40%
2.42
-64.23%
6.76
Selling General And Administration
1.83
-19.79%
2.28
+2.51%
2.23
-7.13%
2.40
General And Administrative Expense
1.83
-19.79%
2.28
+2.51%
2.23
-7.13%
2.40
Salaries And Wages
0.24
-17.18%
0.29
-3.24%
0.30
-50.80%
0.61
Other Gand A
1.59
-20.18%
1.99
+3.41%
1.93
+7.77%
1.79
Other Operating Expenses
0.74
-51.92%
1.53
+21.72%
1.26
+17.55%
1.07
Total Expenses
3.26
-20.94%
4.12
-31.88%
6.05
-41.25%
10.29
Operating Income
-3.26
+20.94%
-4.12
+31.88%
-6.05
+41.25%
-10.29
EBITDA
-3.14
+21.42%
-4.00
+32.26%
-5.91
+42.28%
-10.23
Normalized EBITDA
-3.70
+20.97%
-4.68
+50.90%
-9.54
+24.88%
-12.70
Reconciled Depreciation
0.11
-4.40%
0.12
-16.05%
0.14
+140.25%
0.06
EBIT
-3.26
+20.94%
-4.12
+31.88%
-6.05
+41.25%
-10.29
Total Unusual Items
0.56
-18.33%
0.68
-81.21%
3.63
+47.25%
2.47
Total Unusual Items Excluding Goodwill
0.56
-18.33%
0.68
-81.21%
3.63
+47.25%
2.47
Special Income Charges
-0.00
0.00
0.00
+100.00%
-0.93
Impairment Of Capital Assets
0.00
0.00
0.00
—
Restructuring And Mergern Acquisition
—
0.28
0.00
-100.00%
0.93
Net Income
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Pretax Income
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Net Non Operating Interest Income Expense
0.04
-65.65%
0.12
-51.92%
0.25
+144.76%
0.10
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
0.04
-65.65%
0.12
-51.92%
0.25
+144.76%
0.10
Interest Expense
—
—
—
0.00
Interest Income Non Operating
0.04
-65.65%
0.12
-51.92%
0.25
+150.12%
0.10
Interest Income
0.04
-65.65%
0.12
-51.92%
0.25
+150.12%
0.10
Other Income Expense
0.56
-18.33%
0.68
-81.21%
3.63
+47.25%
2.47
Gain On Sale Of Security
0.56
-18.06%
0.68
-81.21%
3.63
+7.06%
3.39
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Net Income From Continuing Operation Net Minority Interest
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Net Income From Continuing And Discontinued Operation
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Net Income Continuous Operations
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Normalized Income
-3.21
+19.57%
-4.00
+31.01%
-5.79
+43.14%
-10.19
Net Income Common Stockholders
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Diluted EPS
—
-5.75
-5.50%
-5.45
+76.85%
-23.54
Basic EPS
—
-5.75
-5.50%
-5.45
+76.85%
-23.54
Basic Average Shares
—
0.58
+45.25%
0.40
+33.91%
0.30
Diluted Average Shares
—
0.58
+45.25%
0.40
+33.91%
0.30
Diluted NI Availto Com Stockholders
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Amortization
0.03
-15.08%
0.03
-53.37%
0.07
+290.19%
0.02
Amortization Of Intangibles Income Statement
0.03
-15.08%
0.03
-53.37%
0.07
+290.19%
0.02
Depreciation Amortization Depletion Income Statement
0.11
-4.40%
0.12
-16.05%
0.14
+140.25%
0.06
Depreciation And Amortization In Income Statement
0.11
-4.40%
0.12
-16.05%
0.14
+140.25%
0.06
Depreciation Income Statement
0.09
-0.55%
0.09
+17.99%
0.07
+77.90%
0.04
Total Other Finance Cost
-0.04
+65.65%
-0.12
+51.92%
-0.25
-144.76%
-0.10
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
2.68
-34.46%
4.09
-25.12%
5.47
-55.81%
12.37
Current Assets
1.26
-52.89%
2.68
-34.21%
4.07
-62.66%
10.90
Cash Cash Equivalents And Short Term Investments
0.86
-65.05%
2.47
-28.25%
3.45
-66.96%
10.43
Cash And Cash Equivalents
0.86
-65.05%
2.47
-28.25%
3.45
-66.96%
10.43
Cash Equivalents
0.62
-74.36%
2.42
-27.82%
3.35
-49.29%
6.61
Cash Financial
0.24
+354.54%
0.05
-43.49%
0.09
-97.52%
3.82
Receivables
0.08
+354.57%
0.02
-70.95%
0.06
-25.74%
0.08
Accounts Receivable
0.08
+354.57%
0.02
-70.95%
0.06
-25.74%
0.08
Prepaid Assets
0.02
-87.81%
0.19
-21.76%
0.24
-37.58%
0.38
Current Deferred Assets
0.29
0.00
-100.00%
0.32
0.00
Total Non Current Assets
1.42
+0.32%
1.42
+1.33%
1.40
-5.36%
1.48
Net PPE
0.04
+6.75%
0.03
+45.11%
0.02
-74.18%
0.09
Gross PPE
0.32
+37.49%
0.23
+70.32%
0.14
+3.23%
0.13
Accumulated Depreciation
-0.29
-42.82%
-0.20
-75.61%
-0.11
-178.45%
-0.04
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.30
+41.63%
0.21
+84.65%
0.11
+0.00%
0.11
Other Properties
0.02
+0.00%
0.02
+0.00%
0.02
+22.65%
0.02
Goodwill And Other Intangible Assets
0.19
+1.23%
0.18
+4.48%
0.18
-12.30%
0.20
Other Intangible Assets
0.19
+1.23%
0.18
+4.48%
0.18
-12.30%
0.20
Non Current Accounts Receivable
1.20
+0.00%
1.20
+0.00%
1.20
+1.19%
1.19
Total Liabilities Net Minority Interest
0.60
-20.97%
0.76
-8.23%
0.83
-84.64%
5.38
Current Liabilities
0.60
-20.97%
0.76
-8.23%
0.83
-45.35%
1.51
Payables And Accrued Expenses
0.55
+276.20%
0.15
-48.06%
0.28
-80.39%
1.45
Payables
0.40
+370.77%
0.08
-57.09%
0.20
-84.87%
1.29
Accounts Payable
0.40
+370.77%
0.08
-57.09%
0.20
-84.87%
1.29
Current Accrued Expenses
0.16
+150.45%
0.06
-27.88%
0.09
-42.13%
0.15
Current Debt And Capital Lease Obligation
0.04
-3.86%
0.04
+236.97%
0.01
-82.58%
0.07
Current Capital Lease Obligation
0.04
-3.86%
0.04
+236.97%
0.01
-82.58%
0.07
Other Current Liabilities
0.01
-98.60%
0.57
+7.72%
0.53
—
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
3.87
Long Term Debt And Capital Lease Obligation
—
—
0.00
-100.00%
0.01
Long Term Capital Lease Obligation
—
—
0.00
-100.00%
0.01
Stockholders Equity
2.08
-37.53%
3.34
-28.12%
4.64
-33.66%
7.00
Common Stock Equity
2.08
-37.53%
3.34
-28.12%
4.64
-33.66%
7.00
Capital Stock
20.18
+9.14%
18.49
+8.43%
17.06
+3.22%
16.52
Common Stock
20.18
+9.14%
18.49
+8.43%
17.06
+3.22%
16.52
Share Issued
6.96
+99.98%
3.48
+74.17%
2.00
+19.69%
1.67
Ordinary Shares Number
6.96
+99.98%
3.48
+74.17%
2.00
+19.69%
1.67
Retained Earnings
-23.82
-12.55%
-21.17
-18.56%
-17.85
-13.75%
-15.70
Gains Losses Not Affecting Retained Earnings
5.73
-4.36%
5.99
+11480.05%
-0.05
+0.00%
-0.05
Other Equity Adjustments
5.73
-4.36%
5.99
+11480.05%
-0.05
+0.00%
-0.05
Total Equity Gross Minority Interest
2.08
-37.53%
3.34
-28.12%
4.64
-33.66%
7.00
Total Capitalization
2.08
-37.53%
3.34
-28.12%
4.64
-33.66%
7.00
Working Capital
0.66
-65.50%
1.92
-40.83%
3.24
-65.44%
9.38
Invested Capital
2.08
-37.53%
3.34
-28.12%
4.64
-33.66%
7.00
Total Debt
0.04
-3.86%
0.04
+236.97%
0.01
-85.17%
0.08
Capital Lease Obligations
0.04
-3.86%
0.04
+236.97%
0.01
-85.17%
0.08
Net Tangible Assets
1.90
-39.78%
3.15
-29.40%
4.47
-34.28%
6.80
Tangible Book Value
1.90
-39.78%
3.15
-29.40%
4.47
-34.28%
6.80
Derivative Product Liabilities
—
—
0.53
-86.22%
3.85
Other Equity Interest
—
0.02
-99.55%
5.49
-11.72%
6.22
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-2.77
+24.74%
-3.68
+44.12%
-6.58
+19.38%
-8.17
Cash Flow From Continuing Operating Activities
-2.77
+24.74%
-3.68
+44.12%
-6.58
+19.38%
-8.17
Net Income From Continuing Operations
-2.66
+19.83%
-3.31
-53.53%
-2.16
+72.04%
-7.72
Depreciation Amortization Depletion
0.11
-4.40%
0.12
-16.05%
0.14
+140.25%
0.06
Depreciation
0.09
-0.55%
0.09
+17.99%
0.07
+77.90%
0.04
Amortization Cash Flow
0.03
-15.08%
0.03
-53.37%
0.07
+290.19%
0.02
Depreciation And Amortization
0.11
-4.40%
0.12
-16.05%
0.14
+140.25%
0.06
Amortization Of Intangibles
0.03
-15.08%
0.03
-53.37%
0.07
+290.19%
0.02
Other Non Cash Items
—
—
—
0.00
Stock Based Compensation
0.03
-79.47%
0.12
+1.28%
0.12
-75.21%
0.49
Provisionand Write Offof Assets
—
—
—
0.00
Asset Impairment Charge
0.00
0.00
0.00
0.00
Operating Gains Losses
-0.59
+18.58%
-0.72
+80.25%
-3.66
-48.16%
-2.47
Gain Loss On Investment Securities
-0.56
+25.40%
-0.76
+79.24%
-3.64
-47.99%
-2.46
Net Foreign Currency Exchange Gain Loss
-0.02
-169.46%
0.03
+350.68%
-0.01
-113.33%
-0.01
Change In Working Capital
0.34
+187.87%
0.12
+111.33%
-1.03
-169.94%
1.47
Change In Receivables
-0.06
-245.18%
0.04
+104.71%
0.02
+151.20%
-0.04
Changes In Account Receivables
-0.06
-245.18%
0.04
+104.71%
0.02
+151.20%
-0.04
Change In Prepaid Assets
0.16
-21.79%
0.21
+45.92%
0.14
-77.09%
0.62
Change In Payables And Accrued Expense
0.24
+275.50%
-0.13
+88.74%
-1.19
-233.87%
0.89
Investing Cash Flow
-0.29
-657.77%
-0.04
+16.05%
-0.05
-1.45%
-0.05
Cash Flow From Continuing Investing Activities
-0.29
-657.77%
-0.04
+16.05%
-0.05
-1.45%
-0.05
Net PPE Purchase And Sale
0.00
0.00
+100.00%
-0.00
+78.11%
-0.02
Purchase Of PPE
0.00
0.00
+100.00%
-0.00
+78.11%
-0.02
Capital Expenditure
-0.06
-41.87%
-0.04
+16.05%
-0.05
-1.45%
-0.05
Net Intangibles Purchase And Sale
-0.06
-41.87%
-0.04
+7.44%
-0.04
-61.71%
-0.03
Purchase Of Intangibles
-0.06
-41.87%
-0.04
+7.44%
-0.04
-61.71%
-0.03
Net Other Investing Changes
-0.24
—
—
—
Financing Cash Flow
1.43
-48.64%
2.78
+869.85%
-0.36
-109.23%
3.91
Cash Flow From Continuing Financing Activities
1.43
-48.64%
2.78
+869.85%
-0.36
-109.23%
3.91
Net Issuance Payments Of Debt
-0.09
-28.47%
-0.07
-5.50%
-0.07
-223.81%
-0.02
Repayment Of Debt
-0.09
-28.47%
-0.07
-5.50%
-0.07
-223.81%
-0.02
Long Term Debt Payments
-0.09
-28.47%
-0.07
-5.50%
-0.07
-223.81%
-0.02
Net Long Term Debt Issuance
-0.09
-28.47%
-0.07
-5.50%
-0.07
-223.81%
-0.02
Net Common Stock Issuance
2.26
-35.57%
3.50
0.00
-100.00%
5.00
Proceeds From Stock Option Exercised
0.00
-99.92%
0.02
+5498.99%
0.00
+362.50%
0.00
Net Other Financing Charges
-0.74
-10.56%
-0.67
-126.21%
-0.30
+72.33%
-1.07
Changes In Cash
-1.64
-74.42%
-0.94
+86.58%
-6.99
-62.59%
-4.30
Effect Of Exchange Rate Changes
0.03
+175.09%
-0.04
-989.71%
0.00
+102.97%
-0.14
Beginning Cash Position
2.47
-28.25%
3.45
-66.96%
10.43
-29.83%
14.87
End Cash Position
0.86
-65.05%
2.47
-28.25%
3.45
-66.96%
10.43
Free Cash Flow
-2.82
+24.04%
-3.72
+43.92%
-6.63
+19.27%
-8.21
Common Stock Issuance
2.26
-35.57%
3.50
0.00
-100.00%
5.00
Issuance Of Capital Stock
2.26
-35.57%
3.50
0.00
-100.00%
5.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category